The spectrum of oculocutaneous disease : Part II. Neoplastic and drug-related causes of oculocutaneous disease - 16/04/14
Abstract |
There are a multitude of diseases that commonly affect both the skin and the eye. Part II of this 2-part series reviews the oculocutaneous manifestations of neoplasms, both benign and malignant, and adverse drug reactions affecting the skin and the eye. Though rare, a number of neoplasms that primarily involve the skin, such as melanoma and basal cell carcinoma, can metastasize to the eye, leading to permanent damage if not properly treated. In addition, periocular neoplasms can irritate the conjunctiva and lid, reducing a patient's ability to see clearly. Neoplastic diseases, such as xeroderma pigmentosum, Sturge–Weber syndrome, and multiple myeloma, can also lead to permanent changes in the eye if not discovered and managed promptly. Furthermore, there are a multitude of drugs, including those commonly used by dermatologists, which can result in permanent damage to the eye. With proper knowledge of the ocular manifestations and treatment recommendations described in this 2-part series, dermatologists with the assistance of their ophthalmology colleagues can help avoid the complications, including permanent blindness, associated with infectious, inflammatory, genetic, neoplastic, and drug-related conditions.
Le texte complet de cet article est disponible en PDF.Key words : basal cell nevus syndrome, cutaneous T-cell lymphoma, drug reactions, EGFR, inhibitormultiple myeloma, oculocutaneous, periocular neoplasm, PHACES, Stevens-Johnson Syndrome, Sturge Weber Syndrome, toxic epidermal necrolysis, xeroderma pigmentosum
Plan
Funding sources: None. |
|
Dr Alan Menter has reported the following financial relationships: Abbott Laboratories, Consultant, Honorarium; Abbott Laboratories, Speaker, Honorarium; Abbott Laboratories, Principle Investigator, Honorarium; Abbott Laboratories, Advisory Board, Grants/Research Funding; AbbVie, Speaker, Fees; Amgen, Advisory Board, Grants/Research Funding; Amgen, Speaker, Honorarium; Astellas Pharma US, Inc, Advisory Board, Honorarium; Astellas Pharma US, Inc, Consultant, Grants/Research Funding; Celgene Corporation, Principal Investigator, Grants/Research Funding; Centocor Ortho Biotech, Inc, Consultant, Grants/Research Funding; Centocor Ortho Biotech, Inc, Advisory Board, Honorarium; Eli Lilly and Company, Principal Investigator, Grants/Research Funding; Galderma Laboratories, Advisory Board, Honorarium; Galderma Laboratories, Speaker, Honorarium; Genentech, Inc, Advisory Board, Grants/Research Funding; Novartis Pharmaceuticals Corp, Principal Investigator, Grants/Research Funding; Novo Nordisk A/S, Principal Investigator, Grants/Research Funding; Pfizer, Inc, Speaker, Honorarium; Pfizer, Inc, Advisory Board, Honorarium; Pfizer, Inc, Principal Investigator, Grants/Research Funding; Promius Pharma, LLC, Principal Investigator, Grants/Research Funding; Stiefel a GSK company, Principal Investigator, Grants/Research Funding; Syntrix, Principal Investigator, Grants/Research Funding; Warner Chilcott, Advisory Board, Honorarium; Warner Chilcott, Advisory Board, Honorarium. Dr Richard B. Warren has reported the following financial relationships: Abbvie, Advisory Board, Honorarium; AbbVie, Speaker, Honorarium; Amgen, Consultant, Honorarium; Leo, Advisory Board, Honorarium; Leo, Speaker, Honorarium; Pfizer, Inc, Advisory Board, Honorarium; Pfizer, Inc, Speaker, Honorarium; Novartis Pharmaceuticals Corp, Advisory Board, Honorarium; Novartis Pharmaceuticals Corp, Speaker, Honorarium; Novartis Pharmaceuticals Corp, Principal Investigator, Honorarium; Janssen, Advisory Board, Honorarium; Janssen, Speaker, Honorarium. Drs Amanda Abramson and Mahir Patel have no conflicts of interest to disclose and Ms Antoinette Day has no conflicts of interest to disclose. |
Vol 70 - N° 5
P. 821.e1-821.e19 - mai 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?